Both COVID-19 and PAH develop hypoxia as one of their most relevant features and gal3 expression has been shown to be tightly regulated in hypoxic processes, making gal3 an attractive therapeutic target. The gene discussed is LGALS3; the disease is pulmonary arterial hypertension.